



Protein Kinase Inhibitors for Targeted Anticancer Therapies

Guest Editor:

Dr. Katarzyna Malarz

A. Chełkowski Institute of Physics
and Silesian Center for Education
and Interdisciplinary Research,
University of Silesia in Katowice,
75 Pułku Piechoty 1, 41-500
Chorzów, Poland

Deadline for manuscript
submissions:
closed (10 January 2022)

Message from the Guest Editor

Dear Colleagues,

Protein kinase inhibitors are one of the most promising groups of drugs for targeted therapies. According to the latest data, 62 small molecule protein kinase inhibitors have been approved by the Federal Drug Administration (FDA), while at least 150 are being investigated in clinical trials. This is primarily due to a better understanding of the complex signaling network formed by kinases and their mutual relationship in the signal transduction cascades. The kinase activity controls many signaling pathways responsible for major processes associated with cell growth, proliferation, differentiation, or metabolism. However, despite the growing number of inhibitors, there remain many limitations in this field. The development of resistance based on intrinsic and extrinsic pathways, genomic alterations of the primary target, as well as a short response to targeted therapies due to the activation of compensatory signaling pathways are among the main issues.

The aim of this Special Issue is to highlight articles that provide new insights into the discovery of novel protein kinase inhibitors as well as their application in targeted cancer therapies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of
Pharmacy, Rutgers, The State
University of New Jersey, William
Levine Hall, Room 225C, 160
Frelinghuysen Road, Piscataway,
NJ 08854-8020, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma